Hospital Universitari Son Llàtzer, Clinical Analysis Department, Research Institute of Health Sciences (IdIsBa), Palma de Mallorca, Spain.
Hospital Can Misses, Emergency Department, Ibiza, Spain.
J Anal Toxicol. 2019 Jul 24;43(6):497-503. doi: 10.1093/jat/bkz026.
Methoxetamine (MXE) and the arylcyclohexylamines 3-methoxy-PCP (3-MeO-PCP) and 4-methoxy-PCP (4-MeO-PCP) are substituted analogs of the dissociative psychoactive substances ketamine and phencyclidine (PCP), respectively. They have emerged on the new psychoactive substances (NPS) market as legal alternatives to these classically banned dissociatives. Little data has been published regarding the cross-reactivity of these NPS in PCP immunoassays (IAs). The aim of this work was to explore the possibilities of detecting 3-MeO-PCP, 4-MeO-PCP, MXE and ketamine in commercial IAs for PCP. The cross-reactivity study was performed in five different PCP IAs using urine-free, spiked samples and urine samples obtained from two 3-MeO-PCP overdose cases. 3-MeO-PCP and 4-MeO-PCP showed cross-reactivity (ranging from 1-143%) in all PCP IAs evaluated. MXE only showed very weak cross-reactivity (ranged from 0.04 to 0.25%) and ketamine was not detected in any PCP IA evaluated. Urine samples from the two overdose cases were positive for PCP in all IAs evaluated. The commercial PCP IAs evaluated exhibited utility as rapid, preliminary screening techniques for 3-MeO-PCP and 4-MeO-PCP, but not for ketamine. The low reactivity of MXE limits its detectability in the PCP IAs evaluated.
甲氧基苯环己哌啶(MXE)和苯环己哌啶的芳基环己基类似物 3-甲氧基苯环己哌啶(3-MeO-PCP)和 4-甲氧基苯环己哌啶(4-MeO-PCP)分别是分离性精神活性物质氯胺酮和苯环利定(PCP)的取代类似物。它们作为这些经典禁用分离物的合法替代品出现在新型精神活性物质(NPS)市场上。关于这些 NPS 在 PCP 免疫分析(IA)中的交叉反应性,发表的数据很少。这项工作的目的是探索在用于 PCP 的商业 IA 中检测 3-MeO-PCP、4-MeO-PCP、MXE 和氯胺酮的可能性。使用无尿、加标样本和从两个 3-MeO-PCP 过量案例中获得的尿液样本,在五种不同的 PCP IA 中进行了交叉反应性研究。在所有评估的 PCP IA 中,3-MeO-PCP 和 4-MeO-PCP 均显示出交叉反应性(范围为 1-143%)。MXE 仅显示出非常弱的交叉反应性(范围为 0.04 至 0.25%),并且在所有评估的 PCP IA 中均未检测到氯胺酮。从两个过量案例中获得的尿液样本在所有评估的 IA 中均对 PCP 呈阳性。评估的商业 PCP IA 表现出作为 3-MeO-PCP 和 4-MeO-PCP 的快速、初步筛选技术的效用,但不能用于氯胺酮。MXE 的低反应性限制了其在评估的 PCP IA 中的可检测性。